Chronic Granulomatous Disease (CGD)
1
Pipeline Programs
2
Companies
2
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Allergy TherapeuticsUK - West Sussex
1 programEvaluation of Patients With Immune Function AbnormalitiesN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
SomagenetixSGX-001
Allergy TherapeuticsEvaluation of Patients With Immune Function Abnormalities
Clinical Trials (2)
Total enrollment: 3,505 patients across 2 trials
Open-label Gene Therapy Study in p47-CGD
Start: Aug 2026Est. completion: Sep 20285 patients
Phase 1/2Recruiting
Evaluation of Patients With Immune Function Abnormalities
Start: Sep 20053,500 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 3,505 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.